# Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme

> **NCT00704288** · PHASE2 · COMPLETED · sponsor: **Exelixis** · enrollment: 222 (actual)

## Conditions studied

- Glioblastoma Multiforme

## Interventions

- **DRUG:** XL184

## Key facts

- **NCT ID:** NCT00704288
- **Lead sponsor:** Exelixis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2012-06
- **Final completion:** 2012-12
- **Target enrollment:** 222 (ACTUAL)
- **Last updated:** 2024-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00704288

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00704288, "Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00704288. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*